How Does The Filling Line Used For Your Phase I/II Clinical Batch Impact The Long-Term Value Of Your Injectable Therapy?

By Marc Engel, Principal, Technical Operations Engineer, INCOG BioPharma

INCOG BioPharma Services

This website uses cookies to ensure you get the best experience on our website. Learn more